Weekly Digest - Mar 2024

Weekly Digest - Mar 2024

25 Mar 2024: Biocytogen Pharmaceuticals (Beijing) and ABL Bio Inc. announce a collaboration to develop innovative bispecific antibody-drug conjugates (bsADCs)

  • Biocytogen’s RenLite mice platform facilitates the efficient production of fully human antibodies for bsADC development, exhibited potent efficacy and favorable safety in diverse tumor models
  • ABL Bio specializes in Grabody-T and Grabody-B platforms for oncology and neurodegenerative diseases
  • This collaboration merges Biocytogen’s bsADC platform with ABL’s expertise in cancer immunotherapy and CNS disease treatments to accelerate innovative therapy development

For full story click here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home